In palliative therapy, not only were overall PFS and OS measured, but the efficacy between different subgroups was also compared, such as PD-L1-negative versus PD-L1-positive patients, osteogenic sarcoma versus soft tissue sarcoma patients, patients with adverse events versus those without adverse events, and patients treated with monotherapy versus those treated with combination therapy. Here, CD274 is linked to osteosarcoma.